{"@context":{"@vocab":"https://schema.org/"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/fda/warning-letters/recent","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://creativecommons.org/publicdomain/zero/1.0/","primary_source":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters","generated_at":"2026-10-06T08:43:12.202Z"},"count":33,"filters":{"office":"Center for Biologics Evaluation and Research"},"items":[{"id":"e8f9ee22c58977db","posted_date":"2026-03-24","letter_issue_date":"2026-03-17","company_name":"4U Health","issuing_office":"Center for Biologics Evaluation and Research (CBER)","subject":"Premarket Approval/Adulterated","canonical_url":"https://api.morvs.ai/fda-warning/e8f9ee22c58977db"},{"id":"2710837fb8cc9287","posted_date":"2026-02-24","letter_issue_date":"2026-02-11","company_name":"Dynamic Stem Cell Therapy","issuing_office":"Center for Biologics Evaluation and Research","subject":"Unapproved New Drugs/Unlicensed Biological Product Violations","canonical_url":"https://api.morvs.ai/fda-warning/2710837fb8cc9287"},{"id":"3b358d2134b7d7aa","posted_date":"2026-02-10","letter_issue_date":"2026-02-10","company_name":"ProDx Health","issuing_office":"Center for Biologics Evaluation and Research (CBER)","subject":"Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA)","canonical_url":"https://api.morvs.ai/fda-warning/3b358d2134b7d7aa"},{"id":"301ef4652e4f9543","posted_date":"2026-02-10","letter_issue_date":"2026-01-23","company_name":"Louisville Reproductive Center","issuing_office":"Center for Biologics Evaluation and Research","subject":"Deviations/CFR/Regulations for Human Cells, Tissues & Cellular Products (HCT/Ps)","canonical_url":"https://api.morvs.ai/fda-warning/301ef4652e4f9543"},{"id":"55977a77b868da8e","posted_date":"2026-02-10","letter_issue_date":"2026-01-27","company_name":"Conceive Fertility Center","issuing_office":"Center for Biologics Evaluation and Research (CBER)","subject":"Deviations/CFR/Regulations for Human Cells, Tissues & Cellular Products (HCT/Ps)","canonical_url":"https://api.morvs.ai/fda-warning/55977a77b868da8e"},{"id":"5349b66707045327","posted_date":"2026-02-10","letter_issue_date":"2026-01-29","company_name":"Central Coast Multispecialty Medical Group, Inc.","issuing_office":"Center for Biologics Evaluation and Research (CBER)","subject":"Deviations/CFR/Regulations for Human Cells, Tissues & Cellular Products (HCT/Ps)","canonical_url":"https://api.morvs.ai/fda-warning/5349b66707045327"},{"id":"92414cb5b955d5bf","posted_date":"2026-01-20","letter_issue_date":"2026-01-09","company_name":"Germaphobix","issuing_office":"Center for Biologics Evaluation and Research (CBER)","subject":"Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA)","canonical_url":"https://api.morvs.ai/fda-warning/92414cb5b955d5bf"},{"id":"07a5fd1c49c452e1","posted_date":"2026-01-20","letter_issue_date":"2026-01-08","company_name":"Genovate","issuing_office":"Center for Biologics Evaluation and Research (CBER)","subject":"Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA)","canonical_url":"https://api.morvs.ai/fda-warning/07a5fd1c49c452e1"},{"id":"761ae2f15a795eb1","posted_date":"2026-01-20","letter_issue_date":"2026-01-08","company_name":"Genetrace","issuing_office":"Center for Biologics Evaluation and Research (CBER)","subject":"Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA)","canonical_url":"https://api.morvs.ai/fda-warning/761ae2f15a795eb1"},{"id":"8da1326e25b9bb56","posted_date":"2025-05-20","letter_issue_date":"2024-12-16","company_name":"Skye Biologics Holdings LLC","issuing_office":"Center for Biologics Evaluation and Research (CBER)","subject":"Deviations/CFR/Regulations for Human Cells, Tissues & Cellular Products (HCT/Ps)","canonical_url":"https://api.morvs.ai/fda-warning/8da1326e25b9bb56"},{"id":"8a957e0be17c1e1e","posted_date":"2025-05-20","letter_issue_date":"2025-05-05","company_name":"Supreme Rejuvenation, LLC","issuing_office":"Center for Biologics Evaluation and Research","subject":"Unapproved New Drugs/Misbranded","canonical_url":"https://api.morvs.ai/fda-warning/8a957e0be17c1e1e"},{"id":"4bec6e45aa36d0f7","posted_date":"2025-02-25","letter_issue_date":"2025-02-14","company_name":"Sperm Bank, Inc. dba Fertility Center of California","issuing_office":"Center for Biologics Evaluation and Research (CBER)","subject":"Deviations/CFR/Regulations for Human Cells, Tissues & Cellular Products (HCT/Ps)","canonical_url":"https://api.morvs.ai/fda-warning/4bec6e45aa36d0f7"},{"id":"df291a62ca8a6e63","posted_date":"2025-02-04","letter_issue_date":"2025-01-17","company_name":"BioStem Life Sciences","issuing_office":"Center for Biologics Evaluation and Research (CBER)","subject":"Deviations/CFR/Regulations for Human Cells, Tissues & Cellular Products (HCT/Ps)","canonical_url":"https://api.morvs.ai/fda-warning/df291a62ca8a6e63"},{"id":"a8cc84640f748efe","posted_date":"2025-01-28","letter_issue_date":"2025-01-17","company_name":"Chara Biologics, Inc.","issuing_office":"Center for Biologics Evaluation and Research (CBER)","subject":"CGMP/Deviations/Biologics License Application (BLA)","canonical_url":"https://api.morvs.ai/fda-warning/a8cc84640f748efe"},{"id":"fb502d7961f3153c","posted_date":"2025-01-28","letter_issue_date":"2024-12-30","company_name":"Evolutionary Biologics Inc.","issuing_office":"Center for Biologics Evaluation and Research","subject":"Deviations/CFR/Regulations for Human Cells, Tissues & Cellular Products (HCT/Ps)","canonical_url":"https://api.morvs.ai/fda-warning/fb502d7961f3153c"},{"id":"319ecf7e585ff2c2","posted_date":"2025-01-21","letter_issue_date":"2024-12-12","company_name":"INCELL Corporation LLC","issuing_office":"Center for Biologics Evaluation and Research (CBER)","subject":"CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated","canonical_url":"https://api.morvs.ai/fda-warning/319ecf7e585ff2c2"},{"id":"3014eff4e1fb8276","posted_date":"2025-01-07","letter_issue_date":"2024-12-12","company_name":"XO Biologix, LLC","issuing_office":"Center for Biologics Evaluation and Research (CBER)","subject":"Unapproved New Drugs/Adulterated","canonical_url":"https://api.morvs.ai/fda-warning/3014eff4e1fb8276"},{"id":"6bf166e082aa3f55","posted_date":"2024-11-19","letter_issue_date":"2024-11-01","company_name":"Frontier Biologics, LLC","issuing_office":"Center for Biologics Evaluation and Research","subject":"Unapproved New Drug/Unlicensed Biological Product Violations","canonical_url":"https://api.morvs.ai/fda-warning/6bf166e082aa3f55"},{"id":"e2fdad054bcc7286","posted_date":"2024-10-22","letter_issue_date":"2024-10-10","company_name":"Namita A. Goyal, M.D.","issuing_office":"Center for Biologics Evaluation and Research (CBER)","subject":"Clinical Investigator","canonical_url":"https://api.morvs.ai/fda-warning/e2fdad054bcc7286"},{"id":"fcd33e794ea1eaa5","posted_date":"2024-10-22","letter_issue_date":"2024-10-11","company_name":"Blackfly Investments, LLC dba Molecular® Testing Labs","issuing_office":"Center for Biologics Evaluation and Research (CBER)","subject":"Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA)","canonical_url":"https://api.morvs.ai/fda-warning/fcd33e794ea1eaa5"},{"id":"39c9101b692429b0","posted_date":"2024-10-22","letter_issue_date":"2024-10-01","company_name":"Amnio Technology, LLC","issuing_office":"Center for Biologics Evaluation and Research (CBER)","subject":"Deviations/CFR/Regulations for Human Cells, Tissues & Cellular Products (HCT/Ps)","canonical_url":"https://api.morvs.ai/fda-warning/39c9101b692429b0"},{"id":"3226c56c61a92968","posted_date":"2024-10-22","letter_issue_date":"2024-10-01","company_name":"Pinnacle Transplant Technologies, LLC","issuing_office":"Center for Biologics Evaluation and Research (CBER)","subject":"Deviations/CFR/Regulations for Human Cells, Tissues & Cellular Products (HCT/Ps)","canonical_url":"https://api.morvs.ai/fda-warning/3226c56c61a92968"},{"id":"0b112675edc09a0a","posted_date":"2024-10-15","letter_issue_date":"2024-10-08","company_name":"Hemarus LLC","issuing_office":"Center for Biologics Evaluation and Research (CBER)","subject":"CGMP/Blood & Blood Components/Adulterated","canonical_url":"https://api.morvs.ai/fda-warning/0b112675edc09a0a"},{"id":"10a77150d8c5923e","posted_date":"2024-09-06","letter_issue_date":"2024-08-16","company_name":"Regenerative Processing Plant, LLC","issuing_office":"Center for Biologics Evaluation and Research","subject":"CGMP/Finished Pharmaceuticals/Adulterated","canonical_url":"https://api.morvs.ai/fda-warning/10a77150d8c5923e"},{"id":"1c546201d7fadec4","posted_date":"2024-09-03","letter_issue_date":"2024-08-20","company_name":"Mother Stem Institute, Corp.","issuing_office":"Center for Biologics Evaluation and Research (CBER)","subject":"Deviations/CFR/Regulations for Human Cells, Tissues & Cellular Products (HCT/Ps)","canonical_url":"https://api.morvs.ai/fda-warning/1c546201d7fadec4"},{"id":"71fcee04e09c8eb6","posted_date":"2024-08-27","letter_issue_date":"2024-06-28","company_name":"Berkeley Biologics, LLC, previously operating as Elutia, Inc. – Orthobiologics Business Unit, formerly Aziyo Biologics, Inc.","issuing_office":"Center for Biologics Evaluation and Research (CBER)","subject":"Deviations/CFR/Regulations for Human Cells, Tissues & Cellular Products (HCT/Ps)","canonical_url":"https://api.morvs.ai/fda-warning/71fcee04e09c8eb6"},{"id":"4f3733bbc0f95b89","posted_date":"2024-08-27","letter_issue_date":"2024-07-26","company_name":"CARsgen Therapeutics Corporation","issuing_office":"Center for Biologics Evaluation and Research","subject":"CGMP/Finished Pharmaceuticals/Adulterated","canonical_url":"https://api.morvs.ai/fda-warning/4f3733bbc0f95b89"},{"id":"133e64148711ca14","posted_date":"2024-08-13","letter_issue_date":"2024-05-29","company_name":"Konrad Rejdak, M.D., Ph.D.","issuing_office":"Center for Biologics Evaluation and Research (CBER)","subject":"Bioresearch Monitoring Program/IRB","canonical_url":"https://api.morvs.ai/fda-warning/133e64148711ca14"},{"id":"f9a735c9fb1e72fb","posted_date":"2024-07-16","letter_issue_date":"2024-06-21","company_name":"Massachusetts Institute of Technology MIT","issuing_office":"Center for Biologics Evaluation and Research (CBER)","subject":"Bioresearch Monitoring Program/IRB","canonical_url":"https://api.morvs.ai/fda-warning/f9a735c9fb1e72fb"},{"id":"fbff2729f46d5a90","posted_date":"2024-03-12","letter_issue_date":"2024-02-09","company_name":"Human Microbes","issuing_office":"Center for Biologics Evaluation and Research (CBER)","subject":"CGMP/Deviations/Biologics License Application (BLA)","canonical_url":"https://api.morvs.ai/fda-warning/fbff2729f46d5a90"},{"id":"15317168cba57a56","posted_date":"2024-02-13","letter_issue_date":"2024-01-31","company_name":"Barkey GmbH & Co. KG","issuing_office":"Center for Biologics Evaluation and Research (CBER)","subject":"Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA)","canonical_url":"https://api.morvs.ai/fda-warning/15317168cba57a56"},{"id":"49abbc233ecbeecd","posted_date":"2024-01-09","letter_issue_date":"2023-12-20","company_name":"MiMedx Group, Inc.","issuing_office":"Center for Biologics Evaluation and Research (CBER)","subject":"Deviations/CFR/Regulations for Human Cells, Tissues & Cellular Products (HCT/Ps)","canonical_url":"https://api.morvs.ai/fda-warning/49abbc233ecbeecd"},{"id":"c7dc416e80a93ec3","posted_date":"2023-10-25","letter_issue_date":"2023-10-24","company_name":"Abbott Laboratories","issuing_office":"Center for Biologics Evaluation and Research (CBER)","subject":"Dietary Supplement/Adulterated","canonical_url":"https://api.morvs.ai/fda-warning/c7dc416e80a93ec3"}]}